The panel, entitled “Disruptive Thinking: What’s Next for Pain,” focused on ways to address the need for effective pain relief, especially in areas like cancer, trauma and severe chronic pain, particularly in light of efforts to reduce opioid prescription and treat and prevent opioid misuse and addiction.

In her presentation, Baker addressed the NIH HEAL Initiative’s support of biomedical research that helps to end addiction and treats chronic pain.

The panelists included Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences and Kimberly Brandt, Principal Deputy Administrator for Policy & Operations at the Centers for Medicaid & Medicare Services. The panel was moderated by Michael Higgins, Managing Director of Biopharmaceuticals Equity Research at Ladenburg Thalmann & Co. Inc.

Watch Baker’s presentation at BIO Digital.

Rebecca Baker, Ph.D., director of the Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, discussed the latest scientific efforts and her vision of the future for chronic pain research and treatment at BIO Digital, hosted June 8-12, during the BIO International Convention.

#NIHHEAL: Biotechnology Innovation Organization Virtual Conference

Rebecca Baker, Ph.D. presented on biomedical research's role in helping to end addiction long-term.